RxDoctor Payments Data

Walter Margie, MD

Internal Medicine · Ithaca, NYNPI 1427033349

Payments from drug & device makers

$1,061in general payments, 2019–2025

Across 28 payments — averaging $37.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$274
  • AbbVie$244
  • Johnson & Johnson$165
  • Welch Allyn$149
  • Amgen$52
  • Novo Nordisk$42
  • plus $134 from 6 others

What the payments were for

  • Food & beverage$87182%
  • Education$50%
  • Gifts$14914%
  • Other$363%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,061 in reported general payments places this provider in the 70th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$90,411
Medicare patients
317
Services billed
1,575

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide53$117,947
JardianceEmpagliflozin61$65,978
EliquisApixaban59$56,336
TrulicityDulaglutide40$49,527
JanuviaSitagliptin Phosphate36$39,384
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr45$24,627
XareltoRivaroxaban15$22,185
Atorvastatin Calcium488$5,681
SteglatroErtugliflozin Pidolate12$3,734
LantusInsulin Glargine,hum.Rec.Anlog14$3,480
Levothyroxine Sodium243$3,365
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$2,695
Arnuity ElliptaFluticasone Furoate12$2,405
Metoprolol Succinate124$2,354
Metformin Hcl180$2,330

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus$42$117,94753 claims
Boehringer IngelheimJardiance$11$65,97861 claims
Lilly USA, LLCTrulicity$14$49,52740 claims
MerckJanuvia, Steglatro$15$43,11848 claims
GSKAnoro Ellipta, Arnuity Ellipta$34$27,03357 claims
Johnson & JohnsonXarelto$165$22,18515 claims
AbbVieSynthroid$244$1,09125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Ithaca

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →